PDK-1/Akt signaling inhibitors

Details PDK-1/Akt signaling inhibitors PDK-1/Akt signaling inhibitors

2007-09-28

2009-08-18

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S250000, C548S373100, C548S375100, C514S403000

Reexamination Certificate

active

07576116

ABSTRACT:
A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I:wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4alkyl, C1-C4haloalkyl, azido, C1-C4azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof, and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.

REFERENCES:
patent: 5134142 (1992-07-01), Matsuo
patent: 5466823 (1995-11-01), Talley
patent: 5521207 (1996-05-01), Graneto
patent: 5550147 (1996-08-01), Matsuo
patent: 5639777 (1997-06-01), Lee
patent: 5760068 (1998-06-01), Talley
patent: 5972986 (1999-10-01), Seibert
patent: 6025353 (2000-02-01), Masferrer
patent: 7026346 (2006-04-01), Chen
patent: 7183306 (2007-02-01), Shirai
patent: 2002/0032238 (2002-03-01), Priepke
patent: 0418845 (1991-03-01), None
patent: 0554829 (1993-08-01), None
patent: 120841 (2007-07-01), None
patent: WO 96/41626 (1996-12-01), None
patent: WO 03/086287 (2003-10-01), None
patent: WO 2005/044130 (2005-05-01), None
Notice of Allowance in U.S. Appl. No. 10/409,502, mailed Oct. 25, 2005.
Office Action in U.S. Appl. No. 10/409,502, mailed Feb. 17, 2005.
Office Action in U.S. Appl. No. 10/409,502, mailed Jul. 16, 2004.
Office Action in U.S. Appl. No. 10/957,925, mailed Mar. 30, 2007.
Office Action in U.S. Appl. No. 10/957,925, mailed Apr. 18, 2006.
Office Action in U.S. Appl. No. 10/957,925, mailed Oct. 4, 2006.
Office Action in U.S. Appl. No. 11/354,528, mailed Jan. 31, 2008.
Written Opinion in International Application No. PCT/US04/32723, dated Jul. 25, 2005.
International Search Report in International Application No. PCT/US04/32723, dated Jul. 25, 2005.
International Search Report in International Application No. PCT/US03/10738, dated Jan. 21, 2004.
Written Opinion in International Application No. PCT/US03/10738, dated Jun. 4, 2004.
Supplemental Search Report in European Application No. EP03723936, dated Dec. 2, 2005.
Supplemental Search Report in European Application No. EP04816902, dated Jul. 26, 2007.
Examination Report in European Application No. EP03723936, dated Oct. 30, 2007.
Office Action in Chinese application CPCH0661255P, dated Dec. 7, 2007.
“Gastrointestinal (GI) Effects-risk of GI Ulceration, bleeding and perforation,” printed on Mar. 19, 2002 from http://www.celebrex.com/us—prescribing—info.asp (9 pages).
HCAPLUS 1994:8589; CAS Registry No. 151506-47-7.
Product catalog, Cayman Chemical Company, item 10008005 (OSU03012), May 2006 (3 pages).
“Special Project Angiogenesis. Angiogenesis and Cancer,” printed on Dec. 4, 2001 from http://www.med.unibs.it:8080/˜airc/cancer.html (3 pages).
“Special Project Angiogenesis. Angionesis: a Brief Introduction,” printed on Dec. 4, 2001 from http://www.med.unibs.ti:8080/˜airc/angiogen.html (4 pages).
“Understanding Angiogenesis,” printed on Dec. 4, 2001 from http://www.angio.org/understanding/content—understanding. html (6 pages).
“Workshop #2405. Impact of Apoptosis (Programmed Cell Death) for Clinical Laboratory Sciences,” printed on Oct. 22, 2001 from http://www.3dresearch.com/˜apoptosis/cancer/ (6 pages).
De Vleeschauwer et al., “Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles”, Synlett, Thieme International, Stuttgart, DE, No. 4, 375-377 (Apr. 1997).
Grosch et al., “COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib,” FASEB J 15(14): 2742-4. (2001).
Hsu et al., “The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2,” J Biol Chem, 275:11397-403 (2000).
Johnson et al., “The Cyclooxygenase-2 Inhibitor Celecoxib Perturbs Intracellular Calcium by Inhibiting Endoplasmic Reticulum Ca2+-ATPases: A Plausible Link with Its Antitumor Effect and Cardiovascular Risks,” Biochem. J., 363, 831-837 (2002).
Johnson et al., Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41:221-35 (2001).
Penning et al., “Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide(SC-58635, celecoxib),” J Med Chem, 40:1347-65 (1997).
Song et al., “Cyclooxygenase-2, player or spectator in clooxygenase-2 inhibitors-induced apoptosis in prostate cancer cells,” J. Natl. Cancer Inst., 94, 585-591 (2002).
Zhu et al., “Using Cycoloxygenase-2 Inhibitors as Molecular Platforms to Develop a New Class of Apoptosis-Inducing Agents” J. Natl. Cancer Inst. 94, 1745-1757 (2002).
Zhu et al., “From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inibitors,” Cancer Research 64, 4309-4318 (Jun. 15, 2004).

Affiliated with

Also associated with

Rating

PDK-1/Akt signaling inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PDK-1/Akt signaling inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDK-1/Akt signaling inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4119711